Similarly, a difference in the number of heart failure events was observed when CSL112 6-g apoA-I (n=4, 1.0%; P=0.2525) was compared with placebo (n=1, 0.2%) and CSL112 2g apoA-I (n=5, 1.2%; P=0.1205) was compared with placebo. The gene discussed is APOA1; the disease is heart failure.